Oncology Support
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Access global oncology support market intelligence. Drive strategic BD, investment & regulatory insights for pharma. Stay ahead in cancer care innovation.
Showing 1–5 of 5 articles
Quick answer
NovaPharmaNews Oncology Support hub for EMA covers 5 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Duty of care at oncology conferences spotlights planetary health research
NICE Technology Appraisals: Impact on Market Access for Novel Oncology Drugs
HTA Outcomes Oncology Therapies: G-BA vs NICE Post-Brexit Analysis
Mundipharma's REZZAYO (Rezafungin) Meets Primary Endpoint in Phase III ReSPECT Trial for Fungal Disease Prevention
NICE Technology Appraisals & G-BA Assessments for EMA-Approved Oncology Drugs 2026
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.